Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 3NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 41Head and Neck Neoplasms 41Uterine Cervical Neoplasms 31Lung Neoplasms 28Carcinoma, Non-Small-Cell Lung 23Ovarian Neoplasms 16Urinary Bladder Neoplasms 14Stomach Neoplasms 12Carcinoma, Ovarian Epithelial 12Sarcoma 9Neuroblastoma 9Esophageal Neoplasms 9Fallopian Tube Neoplasms 8Medulloblastoma 7Endometrial Neoplasms 7Biliary Tract Neoplasms 7Adenocarcinoma of Lung 7Adenocarcinoma Of Esophagus 7Teratoma 6Central Nervous System Neoplasms 6Brain Neoplasms 6Radiation Injuries 5Neoplasm Metastasis 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Esophageal Squamous Cell Carcinoma 5Brenner Tumor 5Anus Neoplasms 5Urethral Neoplasms 4Testicular Neoplasms 4

Interventions

Doxorubicin 4Cyclophosphamide 4Vincristine 3Rituximab 3Prednisone 3Dexamethasone 3Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Interferon-alpha 2Etoposide 2Cytarabine 2Bortezomib 2tositumomab I-131 1liposomal amphotericin B 1fludarabine 1denileukin diftitox 1Watchful Waiting 1Vancomycin 1VAP-cyclo protocol 1Thalidomide 1Tazobactam 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Palliative Care 1Nutritional Support 1Moxifloxacin 1Morphine 1Methotrexate 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Waldenstrom Macroglobulinemia × Cisplatin × Clear all
NCT00723658 2015-03-06

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

SWOG Cancer Research Network

Phase 2 Withdrawn
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡